Initial supplementary dose of dolutegravir in second-line antiretroviral therapy: a noncomparative, double-blind, randomized placebo-controlled trial
<p><strong>Background:</strong> Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction persists for several weeks after stopping, which could potentially select for dolutegravir re...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2023
|